MedTrace Logo

Efficacy and Safety of Wuling San on Breast Cancer-related Lymphedema

NCT02726477 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2016-05-09

No results posted yet for this study

Summary

The purpose of this study is to assess the efficacy and safety of Wuling San, a traditional Chinese medicine, in reducing arm volume excess in women with stage I-II breast cancer related unilateral lymphedema.

Conditions

Interventions

DRUG

Wuling San

Patients will be administrated with Wuling San at a dosage of 1g/kg twice a day after randomisation.

DRUG

placebo

Patients will be administrated with placebo powder at a dosage of 1g/kg twice a day after randomisation.

Sponsors & Collaborators

  • Liuzhou Maternity and Child Healthcare Hospital

    collaborator OTHER

  • Liuzhou Hospital of Traditional Chinese Medicine

    collaborator OTHER

  • Fourth Affiliated Hospital of Guangxi Medical University

    lead OTHER

Principal Investigators

  • Xiangcheng Wei · Guangxi Medical University Institutional Review Board

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2017-09-30
Completion
2018-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02726477 on ClinicalTrials.gov